TUMOR-TARGETED SUPERANTIGENS - Fusion Protein Technologies for Biopharmaceuticals: Applications and Challenges - page 369

for T-cell immunotherapy of human B-lineage malignancies.
Blood 89, 2089-2097.
46. Hole N, Stern PL. (1988) A 72 kD trophoblast glycoprotein
defined by a monoclonal antibody. Br. J. Cancer 57, 239-246.
47. Hole N, Stern PL. (1990) Isolation and characterization of 5T4,
a tumour-associated antigen. Int. J. Cancer 45, 179-184.
48. Southgate TD, McGinn OJ, Castro FV, Rutkowski AJ, Al-
Muftah M, Marinov G, et al. (2010) CXCR4 mediated chemo-
taxis is regulated by 5T4 oncofetal glycoprotein in mouse
embryonic cells. PLoS One 5, e9982.
49. Starzynska T, Marsh PJ, Schofield PF, Roberts SA, Myers KA,
Stern PL. (1994) Prognostic significance of 5T4 oncofetal
antigen expression in colorectal carcinoma. Br. J. Cancer
69, 899-902.
50. Southall PJ, Boxer GM, Bagshawe KD, Hole N, Bromley M,
Stern PL. (1990) Immunohistological distribution of 5T4 anti-
gen in normal and malignant tissues. Br. J. Cancer 61, 89-95.
51. Jones H, Roberts G, Hole N, McDicken IW, Stern P. (1990)
Investigation of expression of 5T4 antigen in cervical cancer.
Br. J. Cancer 61, 96-100.
52. Naganuma H, Kono K, Mori Y, Takayoshi S, Stern PL, Tasaka
K, et al. (2002) Oncofetal antigen 5T4 expression as a prog-
nostic factor in patients with gastric cancer. Anticancer Res.
22, 1033-1038.
53. Starzynska T, Rahi V, Stern PL. (1992) The expression of 5T4
antigen in colorectal and gastric carcinoma. Br. J. Cancer 66,
867-869.
54. Starzynska T, Wiechowska-Kozlowska A, Marlicz K, Bromley
M, Roberts SA, Lawniczak M, et al. (1998) 5T4 oncofetal
antigen in gastric carcinoma and its clinical significance. Eur.
J. Gastroenterol. Hepatol. 10, 479-484.
55. Wrigley E, McGown AT, Rennison J, Swindell R, Crowther D,
Starzynska T, et al. (1995) 5T4 oncofetal antigen expression in
ovarian carcinoma. Int. J. Gynecol. Cancer 5, 269-274.
56. Connor ME, Stern PL. (1990) Loss of MHC class-I expression
in cervical carcinomas. Int. J. Cancer 46, 1029-1034.
57. Griffiths RW, Gilham DE, Dangoor A, Ramani V, Clarke NW,
Stern PL, et al. (2005) Expression of the 5T4 oncofoetal
antigen in renal cell carcinoma: a potential target for T-cell-
based immunotherapy. Br. J. Cancer 93, 670-677.
58. Cheng JD, Babb JS, Langer C, Aamdal S, Robert F, Engelhardt
LR, et al. (2004) Individualized patient dosing in Phase I
clinical trials: the role of escalation with overdose control in
PNU-214936. J. Clin. Oncol. 22, 602-609.
59. Motzer RJ. (2003) Prognostic factors and clinical trials of new
agents in patients with metastatic renal cell carcinoma. Crit.
Rev. Oncol. Hematol. 46(Suppl), S33-S39.
60. Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, Marion S,
et al. (2004) Prognostic factors for survival in previously
treated patients with metastatic renal cell carcinoma. J.
Clin. Oncol. 22, 454-463.
61. Robinson MK, Alpaugh RK, Borghaei H. (2010) Naptumomab
estafenatox: a new immunoconjugate. Expert Opin. Biol. Ther.
10, 273-279.

62. Kodumudi KN, Woan K, Gilvary DL, Sahakian E, Wei S, Djeu
JY. (2010) A novel chemoimmunomodulating property of
docetaxel: suppression of myeloid-derived suppressor cells
in tumor bearers. Clin. Cancer Res. 16, 4583-4594.
63. Montero A, Fossella F, Hortobagyi G, Valero V. (2005) Doce-
taxel for treatment of solid tumours: a systematic review of
clinical data. Lancet Oncol. 6, 229-239.
64. Toschi L, Finocchiaro G, Bartolini S, Gioia V, Cappuzzo F. (2005)
Role of gemcitabine in cancer therapy. Future Oncol. 1, 7-17.
65. Chow LQ, Eckhardt SG. (2007) Sunitinib: from rational design
to clinical efficacy. J. Clin. Oncol. 25, 884-896.
66. Jenab-Wolcott J, Giantonio BJ. (2009) Bevacizumab: current
indications and future development for management of solid
tumors. Expert Opin. Biol. Ther. 9, 507-517.
67. Schadendorf D, Algarra SM, Bastholt L, Cinat G, Dreno B,
Eggermont AM, et al. (2009) Immunotherapy of distant meta-
static disease. Ann. Oncol. 20(Suppl 6), vi41-vi50.
68. McDermott DF. (2009) Immunotherapy of metastatic renal cell
carcinoma. Cancer 115, 2298-2305.
69. Rech AJ, Vonderheide RH. (2009) Clinical use of anti-CD25
antibody daclizumab to enhance immune responses to tumor
antigen vaccination by targeting regulatory T cells. Ann. N Y
Acad. Sci. 1174, 99-106.
70. Sarnaik AA, Weber JS. (2009) Recent advances using anti-
CTLA-4 for the treatment of melanoma. Cancer J. 15, 169-173.
71. Peranzoni E, Zilio S, Marigo I, Dolcetti L, Zanovello P,
Mandruzzato S, et al. (2010) Myeloid-derived suppressor
cell heterogeneity and subset definition. Curr. Opin. Immunol.
22, 238-244.
72. Sinha P, Clements VK, Bunt SK, Albelda SM, Ostrand-Rosen-
berg S. (2007) Cross-talk between myeloid-derived suppressor
cells and macrophages subverts tumor immunity toward a type
2 response. J. Immunol. 179, 977-983.
73. Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM. (2005)
Gemcitabine selectively eliminates splenic Gr-1 þ /CD11b þ mye-
loid suppressor cells in tumor-bearing animals and enhances
antitumor immune activity. Clin. Cancer Res. 11, 6713-6721.
74. Sundstedt A, Celander M, Eriksson H, T¨rngren M, Hedlund
G. (2012) Monotherapeutically nonactive CTLA-4 blockade
results in greatly enhanced antitumor effects when combined
with tumor-targeted superantigens in a B16 melanoma model.
J Immunother. 35(4): 344-353.
75. Rini BI. (2009) Metastatic renal cell carcinoma: many treat-
ment options, one patient. J. Clin. Oncol. 27, 3225-3234.
76. Di Lorenzo G, Autorino R, Sternberg CN. (2009) Metastatic
renal cell carcinoma: recent advances in the targeted therapy
era. Eur. Urol. 56, 959-971.
77. Azzoli CG, Baker S, Jr, Temin S, Pao W, Aliff T, Brahmer J, et
al. (2009) American society of clinical oncology clinical
practice guideline update on chemotherapy for stage IV
non-small-cell lung cancer. J. Clin. Oncol. 27, 6251-6266.
78. Langer CJ, Besse B, Gualberto A, Brambilla E, Soria JC.
(2010) The evolving role of histology in the management of
advanced non-small-cell lung cancer. J. Clin. Oncol.